ReviewApplied microbiology and biotechnology2022
Bioactive components of Laetiporus species and their pharmacological effects.
Review in Applied microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Genome mining reveals the unique function of UbiA-type prenyltransferase in Laetiporus sulphureus.Natural products and bioprospecting · 2026Article
- Article
- Screening of Basidiomycete Strains Capable of Synthesizing Antibacterial and Antifungal Metabolites.International journal of molecular sciences · 2025Article
- Secondary Metabolites ofJournal of fungi (Basel, Switzerland) · 2024Review
- Physicochemical Properties of Different Sulfated Polysaccharide Components fromJournal of fungi (Basel, Switzerland) · 2024Article
- Article
- Progress in pathogenesis research of Ustilago maydis, and the metabolites involved along with their biosynthesis.Molecular plant pathology · 2023Review
- The Possibility of Using Sulphur Shelf Fungus (Foods (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Laetiporus species are brown rot fungi belonging to the order Polyporales in the division Basidiomycota. These species produce a variety of metabolites and provide a great source of natural material for the screening of medicinally active natural products or their derivatives. This review summarizes the research progress on bioactive metabolites of Laetiporus species up to April 2022, including biological macromolecules, for instance, polysaccharides and lectins, as well as 80 reported small molecule chemical components (15 sterols, 29 triterpenes, 10 sesquiterpenes, 5 polyenes, 10 volatile compounds, and 11 other compounds). These metabolites exhibit antimicrobial, anticancer, antioxidant, hepatoprotective, anti-inflammatory, and antidiabetic activities. Genome mining predicted 23 terpene synthases, 7 polyketide synthases, and 9 non-ribosomal peptide synthases involved in bioactive metabolites biosynthesis, which were analyzed by antiSMASH in L. sulphureus genome. This review will provide a basis for the biosynthesis of active components in Laetiporus species and a reference for the research of medical precursors. KEY POINTS: • The mini-review summarized 80 secondary metabolites of Laetiporus spp. • The main pharmacological activities of Laetiporus spp. were summarized. • Biosynthetic genes of terpenoids, polyketides, and non-ribosomal peptides were also summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.